Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMO | Q99835 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13407135 | 0.85 | TRPV1 (0.52) | TRPV1MEN1KMT2ASMOGFER | |
| SCHEMBL8339118 | 0.76 | BPTF (0.50) | TRPV1MEN1KMT2AALDH1A1 | |
| SCHEMBL3417311 | 0.75 | AKR1C3 (0.35) | TRPV1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL14735613 | 0.75 | KMT2A (0.38) | TRPV1MEN1KMT2ASMOALDH1A1 | |
| SCHEMBL8336910 | 0.74 | TRPV1 (1.00) | TRPV1MAPTALDH1A1 | |
| SCHEMBL1752994 | 0.74 | TRPV1 (0.44) | TRPV1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL3541707 | 0.74 | TRPV1 (0.62) | TRPV1MEN1KMT2ASMOLMNA | |
| SCHEMBL8338212 | 0.74 | TRPV1 (1.00) | TRPV1MAPT | |
| SCHEMBL29270326 | 0.72 | JAK3 (0.40) | TRPV1 | |
| SCHEMBL20296761 | 0.72 | SMO (0.46) | MEN1KMT2ASMOGFERUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696207-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080200472-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2008-08-21 | — | — | US | disclosed |
| US-7262194-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2007-08-28 | — | — | US | disclosed |
| WO-2004011441-A1 | PYRIDAZINYLPIPERAZINE DERIVATIVES FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200472-A1 | Therapeutic agents useful for treating pain | HRH2, OPRL1, TRPV1 | TRPV1 3/4885MEN1 4723/4885KMT2A 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.